Arcturus Therapeutics says ARCT-810 safe and well tolerated in Phase 2 urea cycle disorder study

Arcturus Therapeutics said ARCT-810 was generally safe and well tolerated and showed encouraging activity across key urea cycle biomarkers in its ongoing Phase 2 study.

Detected & updated continuously · Source: Nebula